Innovent Biologics Inc (HKEX: 01801), a biopharmaceutical company that develops, manufactures and commercialises high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases, announced on Thursday that it has dosed its first patient in a Phase II basket trial of taletrectinib for solid tumours containing NTRK fusion (NCT04617054).
The company signed an exclusive agreement with AnHeart Therapeutics Co. Ltd. on June 2021. Under the contract, Innovent Biologics Inc received rights to co-develop and commercialise taletrectinib in Greater China.
The product is an investigational next-generation tyrosine kinase inhibitor aimed at effectively targeting ROS1 and NTRK fusion mutations with potential to treat TKI-naive or pre-treated patients.
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
Amneal announces launch of PEMRYDI RTU, a ready-to-use oncology injectable
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Medivir and Vetbiolix report positive results from VBX-1000 Proof-of-Concept clinical study
Norgine submits first marketing authorisation application submissions for approval of eflornithine
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Precision Epigenomics partners with TruDiagnostic
Portage Biotech expands evaluation of strategic alternatives
Stamford Pharmaceuticals starts locally advanced basal cell carcinoma (laBCC) trial of SP-002
Soligenix receives orphan drug designation from FDA for active ingredient in SuVax